8.93

1.36% 0.12

Relay Therapeutics Inc (RLAY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RLAY Giù? Forum Previsione

Precedente Chiudi:

$8.81

Aprire:

$8.85

Volume 24 ore:

2.05M

Relative Volume:

0.91

Capitalizzazione di mercato:

$1.55B

Reddito:

$25.55M

Utile/perdita netta:

$-341.97M

Rapporto P/E:

-3.1893

EPS:

-2.8

Flusso di cassa netto:

$-304.44M

1 W Prestazione:

+0.11%

1M Prestazione:

+12.47%

6M Prestazione:

+161.11%

1 anno Prestazione:

+125.51%

Intervallo 1D:

$8.85

$9.54

Intervallo di 1 settimana:

$8.35

$9.54

Portata 52W:

$1.775

$9.54

Relay Therapeutics Inc Stock (RLAY) Company Profile

Nome

Relay Therapeutics Inc

Settore

Healthcare (1111)

Industria

Biotechnology (622)

Telefono

617-370-8837

Indirizzo

60 HAMPSHIRE STREET, CAMBRIDGE

Dipendente

197

Cinguettio

Prossima data di guadagno

2025-02-21

Ultimi documenti SEC

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RLAY Relay Therapeutics Inc	8.93	1.53B	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-26	Aggiornamento	Oppenheimer	Perform → Outperform
2025-12-12	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2025-09-04	Ripresa	Guggenheim	Buy
2025-04-17	Iniziato	Wells Fargo	Equal Weight
2024-09-10	Ripresa	Goldman	Buy
2024-09-10	Aggiornamento	Jefferies	Hold → Buy
2024-09-10	Downgrade	Oppenheimer	Outperform → Perform
2024-05-10	Aggiornamento	Barclays	Equal Weight → Overweight
2023-04-20	Aggiornamento	Jefferies	Underperform → Hold
2023-04-19	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-04-13	Iniziato	Raymond James	Outperform
2023-02-03	Iniziato	Oppenheimer	Outperform
2022-09-30	Iniziato	Barclays	Equal Weight
2022-09-02	Iniziato	Stifel	Buy
2022-06-06	Iniziato	Jefferies	Underperform
2022-02-01	Iniziato	Berenberg	Buy
2021-07-21	Iniziato	BofA Securities	Buy
2020-12-15	Reiterato	H.C. Wainwright	Buy
2020-12-08	Iniziato	JMP Securities	Mkt Outperform
2020-11-05	Iniziato	H.C. Wainwright	Buy
2020-08-10	Iniziato	Cowen	Outperform
2020-08-10	Iniziato	Goldman	Buy
2020-08-10	Iniziato	Guggenheim	Buy
2020-08-10	Iniziato	JP Morgan	Neutral

Mostra tutto

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

Feb 13, 2026

Will Relay Therapeutics Inc. benefit from government policy2025 Price Targets & Free Community Supported Trade Ideas - mfd.ru

Feb 13, 2026

Can Relay Therapeutics Inc. expand its profit marginsPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru

Feb 13, 2026

Feb 11, 2026

Can Relay Therapeutics Inc. sustain its profitability2025 Bull vs Bear & Low Risk High Reward Trade Ideas - mfd.ru

Feb 11, 2026

Feb 10, 2026

Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com South Africa

Feb 10, 2026

Feb 09, 2026

Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat

Feb 09, 2026

Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com

Feb 09, 2026

Feb 08, 2026

Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm

Feb 08, 2026

Feb 07, 2026

Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance

Feb 07, 2026

Feb 06, 2026

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail

Feb 06, 2026

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga

Feb 05, 2026

Feb 04, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network

Feb 04, 2026

Feb 03, 2026

Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter

Feb 03, 2026

Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com

Feb 03, 2026

Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView

Feb 03, 2026

Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire

Feb 03, 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - The Manila Times

Feb 03, 2026

Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Feb 03, 2026

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz

Feb 02, 2026

Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance

Feb 02, 2026

Feb 01, 2026

Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn

Feb 01, 2026

Jan 31, 2026

Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026